Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TOP3A (ImmuneEditome ID:7156)

1. Gene summary of enriched editing regions for TOP3A

Gene summary

Gene information	Gene symbol	TOP3A
	Gene ID	7156
	GeneSynonyms	MGRISCE2\|PEOB5\|TOP3\|ZGRF7
	GeneCytomap	17p11.2
	GeneType	protein-coding
	GeneDescription	DNA topoisomerase 3-alpha\|topo III-alpha\|topoisomerase (DNA) III alpha\|zinc finger, GRF-type containing 7
	GeneModificationdate	20230518
	UniprotID	Q13472;J3KS96;K7ELI7;J3QR18;J3QS25;J3KRR9
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr17:18271785-18274258:-	ENST00000469739.5	ENSG00000177302.13	TOP3A	ncRNA_exonic	AluSq,AluSq2,MIRc,L1MB5,AluJr,AluSx3	chr17:18271785-18274258:-.alignment
chr17:18287817-18288458:-	ENST00000469739.5	ENSG00000177302.13	TOP3A	ncRNA_intronic	AluSq,L1MB8,(TA)n,AluSx3	chr17:18287817-18288458:-.alignment
chr17:18306044-18306687:-	ENST00000472959.4	ENSG00000177302.13	TOP3A	ncRNA_exonic	AluJb,AluSq10	chr17:18306044-18306687:-.alignment
chr17:18306044-18306687:-	ENST00000583328.4	ENSG00000177302.13	TOP3A	ncRNA_exonic	AluJb,AluSq10	chr17:18306044-18306687:-.alignment

Top

2. Tumor-specific enriched editing regions for TOP3A

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr17:18271785-18274258:-	KIRC	EER	8.1159e-03
ENSG00000177302.13,TOP3A	KIRC	EAG	9.9584e-03
chr17:18271785-18274258:-	KIRP	EER	2.1631e-04
ENSG00000177302.13,TOP3A	KIRP	EAG	2.4707e-04

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
chr17:18271785-18274258:-	KIRP	Cli	EER	2.3519e-02	6.2633e-03	0.2114
ENSG00000177302.13,TOP3A	KIRP	Cli	EAG	1.2007e-02	3.8210e-03	0.2234

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for TOP3A

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr17:18271785-18274258:-

GBM

EER

ENSG00000188765,TMSB4XP2

0.3315

3.4586e-03

1.4047e-09

0.4583

T_cells_gamma_delta

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr17:18271785-18274258:-

GBM

EER

ENSG00000279461,AC005480.1

0.3166

5.7764e-03

7.7607e-09

0.4392

T_cells_gamma_delta

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:18271785-18274258:-

GBM

EER

ENSG00000205579,DYNLL1P1

0.3065

8.6180e-03

1.7860e-07

0.4009

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr17:18271785-18274258:-

GBM

EER

ENSG00000180389,ATP5EP2

0.3054

8.9220e-03

9.6931e-12

0.5079

T_cells_gamma_delta

GSVA_HALLMARK_MITOTIC_SPINDLE

chr17:18271785-18274258:-

GBM

EER

ENSG00000256745,RP11-680H20.1

0.3033

9.5413e-03

1.3432e-08

0.4329

Macrophages_M2

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr17:18271785-18274258:-

GBM

EER

ENSG00000236876,TMSB4XP1

0.3006

9.5731e-03

1.6190e-08

0.4307

Macrophages_M2

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr17:18271785-18274258:-

GBM

EER

ENSG00000261557,EEF1A1P38

0.2927

1.2104e-02

3.8549e-08

0.4203

T_cells_CD4_memory_resting

GSVA_HALLMARK_KRAS_SIGNALING_DN

chr17:18271785-18274258:-

GBM

EER

ENSG00000263781,RP11-321A17.3

0.2916

1.3036e-02

5.8169e-09

0.4425

T_cells_gamma_delta

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

chr17:18271785-18274258:-

GBM

EER

ENSG00000256338,RPL41P2

0.2900

1.3804e-02

5.7206e-10

0.4678

T_cells_gamma_delta

GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION

chr17:18271785-18274258:-

GBM

EER

ENSG00000228118,LOC124685

0.2868

1.5208e-02

3.1969e-11

0.4967

T_cells_gamma_delta

GSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results

Top

4. Enriched editing regions and immune related splicing for TOP3A

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000177302.13,TOP3A

COAD

EAG

ENSG00000171552.8

chr20

31722617:31722860:31721654:31722330:31721654:31722348

0.2587

2.7128e-02

4.7438e-12

0.4526

ACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SF3A3;SF3B4;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1

BCL2L1

Dendritic_cells_activated

GSVA_HALLMARK_BILE_ACID_METABOLISM

ENSG00000177302.13,TOP3A

COAD

EAG

ENSG00000071242.7

chr6

166451102:166451233:166448723:166448846:166448723:166448849

0.0653

8.6015e-03

3.1832e-13

0.5172

ACIN1;ADAR;AIFM1;BCCIP;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LIN28;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM47;SAFB2;SLTM;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF2;UPF1;VIM;XRN2;YTHDC1;YWHAG

RPS6KA2

Dendritic_cells_activated

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

ENSG00000177302.13,TOP3A

GBM

EAG

MEX

ENSG00000129657.10

chr17

77213917:77215740:77215857:77216335:77216348:77216387:77216413:77216802

0.2832

3.5231e-03

9.9179e-07

0.4294

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

ENSG00000177302.13,TOP3A

GBM

EAG

MEX

ENSG00000129657.10

chr17

77213917:77215740:77215857:77216335:77216361:77216387:77216413:77216802

0.2832

3.5231e-03

9.9179e-07

0.4294

ENSG00000177302.13,TOP3A

GBM

EAG

ENSG00000056736.5

chr3

53858718:53858818:53857615:53857690:53857615:53858435

-0.2964

1.7847e-02

4.2660e-07

-0.4053

ADAR;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184

IL17RB

T_cells_CD4_memory_activated

GSVA_HALLMARK_ANDROGEN_RESPONSE

chr17:18271785-18274258:-

GBM

EER

ENSG00000056736.5

chr3

53858718:53858818:53857615:53857690:53857615:53858435

-0.2966

1.5237e-02

3.8391e-07

-0.4067

IL17RB

T_cells_CD4_memory_activated

GSVA_HALLMARK_ANDROGEN_RESPONSE

chr17:18271785-18274258:-

GBM

EER

MEX

ENSG00000129657.10

chr17

77213917:77215740:77215857:77216335:77216348:77216387:77216413:77216802

0.2836

2.9629e-03

9.4701e-07

0.4301

chr17:18271785-18274258:-

GBM

EER

MEX

ENSG00000129657.10

chr17

77213917:77215740:77215857:77216335:77216361:77216387:77216413:77216802

0.2836

2.9629e-03

9.4701e-07

0.4301

ENSG00000177302.13,TOP3A

TGCT

EAG

ENSG00000147140.11

chrX

71283693:71283721:71284396:71284453:71290628:71290791

0.4710

3.5775e-06

7.6568e-09

0.4446

ACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184

B_cells_naive

GSVA_HALLMARK_GLYCOLYSIS

chr17:18271785-18274258:-

TGCT

EER

ENSG00000111752.6

chr12

8920984:8921065:8919755:8919866:8919755:8919917

-0.3622

6.7049e-04

4.6816e-08

-0.4374

B_cells_naive

GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results

Top

5. Enriched editing regions and immune infiltration for TOP3A

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr17:18271785-18274258:-	BLCA	EER	Macrophages_M1	3.8201e-03	0.1515
ENSG00000177302.13,TOP3A	BLCA	EAG	Macrophages_M1	4.2210e-03	0.1498
chr17:18271785-18274258:-	BRCA	EER	B_cells_naive	2.7354e-02	-0.0685
ENSG00000177302.13,TOP3A	BRCA	EAG	Dendritic_cells_activated	2.2065e-02	0.0709
chr17:18271785-18274258:-	COAD	EER	Neutrophils	6.6614e-03	0.1867
ENSG00000177302.13,TOP3A	COAD	EAG	Neutrophils	2.6338e-03	0.2060
ENSG00000177302.13,TOP3A	DLBC	EAG	Mast_cells_resting	7.1146e-03	0.3876
chr17:18271785-18274258:-	ESCA	EER	T_cells_CD4_naive	4.6207e-02	0.1578
chr17:18271785-18274258:-	GBM	EER	Macrophages_M0	1.4260e-03	-0.2516
ENSG00000177302.13,TOP3A	GBM	EAG	Macrophages_M0	1.3252e-03	-0.2532
chr17:18271785-18274258:-	HNSC	EER	Dendritic_cells_activated	3.4248e-02	0.1006
ENSG00000177302.13,TOP3A	HNSC	EAG	Dendritic_cells_activated	3.4506e-02	0.1005
ENSG00000177302.13,TOP3A	KICH	EAG	NK_cells_activated	3.8938e-02	-0.3022
chr17:18271785-18274258:-	KIRC	EER	Monocytes	3.4256e-02	-0.1164
ENSG00000177302.13,TOP3A	KIRC	EAG	Monocytes	2.3773e-02	-0.1241
chr17:18271785-18274258:-	KIRP	EER	Macrophages_M1	8.3655e-03	0.1702
ENSG00000177302.13,TOP3A	KIRP	EAG	Macrophages_M1	5.7522e-03	0.1781
chr17:18271785-18274258:-	LAML	EER	Eosinophils	3.1819e-02	0.2240
chr17:18271785-18274258:-	LGG	EER	Neutrophils	2.0608e-02	0.1021
ENSG00000177302.13,TOP3A	LGG	EAG	Neutrophils	2.0706e-02	0.1020
chr17:18271785-18274258:-	LIHC	EER	Macrophages_M0	6.1474e-03	-0.1664
ENSG00000177302.13,TOP3A	LIHC	EAG	Macrophages_M0	6.1474e-03	-0.1664
chr17:18271785-18274258:-	LUSC	EER	Neutrophils	2.7039e-04	0.1732
ENSG00000177302.13,TOP3A	LUSC	EAG	Neutrophils	2.7931e-04	0.1728
ENSG00000177302.13,TOP3A	MESO	EAG	T_cells_regulatory_(Tregs)	3.0794e-02	-0.2603
chr17:18271785-18274258:-	OV	EER	B_cells_memory	1.3495e-02	0.1513
ENSG00000177302.13,TOP3A	OV	EAG	B_cells_memory	8.7933e-03	0.1604
chr17:18271785-18274258:-	PAAD	EER	Dendritic_cells_activated	2.8595e-02	0.1899
ENSG00000177302.13,TOP3A	PAAD	EAG	Dendritic_cells_activated	2.8595e-02	0.1899
chr17:18271785-18274258:-	PCPG	EER	T_cells_CD4_memory_resting	2.2914e-02	-0.1827
ENSG00000177302.13,TOP3A	PCPG	EAG	T_cells_CD4_memory_resting	2.2914e-02	-0.1827
chr17:18271785-18274258:-	PRAD	EER	T_cells_CD4_memory_resting	1.3233e-04	0.1802
ENSG00000177302.13,TOP3A	PRAD	EAG	T_cells_CD4_memory_resting	1.3175e-04	0.1803
ENSG00000177302.13,TOP3A	READ	EAG	Macrophages_M1	1.7647e-03	-0.3806
chr17:18271785-18274258:-	STAD	EER	T_cells_CD4_memory_activated	1.3010e-02	0.1346
chr17:18287817-18288458:-	STAD	EER	T_cells_regulatory_(Tregs)	4.3121e-02	-0.4076
ENSG00000177302.13,TOP3A	STAD	EAG	T_cells_CD4_memory_activated	1.7644e-02	0.1286
chr17:18271785-18274258:-	TGCT	EER	Macrophages_M2	2.5012e-06	-0.3678
ENSG00000177302.13,TOP3A	TGCT	EAG	Macrophages_M2	2.5012e-06	-0.3678
chr17:18271785-18274258:-	THYM	EER	Macrophages_M1	1.8509e-10	0.5546
ENSG00000177302.13,TOP3A	THYM	EAG	Macrophages_M1	1.8509e-10	0.5546
chr17:18271785-18274258:-	UCEC	EER	Dendritic_cells_activated	8.5387e-04	0.2549
ENSG00000177302.13,TOP3A	UCEC	EAG	Dendritic_cells_activated	7.7914e-04	0.2568
chr17:18271785-18274258:-	UCS	EER	B_cells_memory	4.9774e-02	0.2659
ENSG00000177302.13,TOP3A	UCS	EAG	B_cells_memory	4.9774e-02	0.2659

Top

6. Enriched editing regions and immune gene sets for TOP3A

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events

cancer

Type

E2M_P

Boxplot

CorP

CorR

CorrelationPlot

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr17:18271785-18274258:-	THYM	EER	9.0049e-04	-0.3081	5.0487e-03	-0.2621	3.2044e-06	0.4222	2.1758e-07	0.4646
ENSG00000177302.13,TOP3A	THYM	EAG	9.0049e-04	-0.3081	5.0487e-03	-0.2621	3.2044e-06	0.4222	2.1758e-07	0.4646

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr17:18271785-18274258:-	ACC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	1.8340e-02	0.2875
ENSG00000177302.13,TOP3A	ACC	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EAG	1.8340e-02	0.2875
ENSG00000177302.13,TOP3A	BLCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	2.1520e-04	0.1931
chr17:18271785-18274258:-	BLCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	1.2453e-04	0.2000
ENSG00000177302.13,TOP3A	BRCA	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EAG	1.7897e-06	0.1473
chr17:18271785-18274258:-	BRCA	GSVA_HALLMARK_CHOLESTEROL_HOMEOSTASIS	EER	7.4390e-08	0.1660
chr17:18271785-18274258:-	CESC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	6.5154e-04	0.1961
ENSG00000177302.13,TOP3A	CESC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	7.0213e-04	0.1949
ENSG00000177302.13,TOP3A	CHOL	GSVA_HALLMARK_FATTY_ACID_METABOLISM	EAG	7.0527e-03	0.4816
chr17:18271785-18274258:-	COAD	GSVA_HALLMARK_E2F_TARGETS	EER	2.1563e-04	-0.2527
ENSG00000177302.13,TOP3A	COAD	GSVA_HALLMARK_DNA_REPAIR	EAG	7.2819e-06	-0.3033
chr17:18271785-18274258:-	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	4.0879e-02	-0.1619
ENSG00000177302.13,TOP3A	ESCA	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	1.3374e-02	-0.1952
ENSG00000177302.13,TOP3A	GBM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	1.0167e-03	-0.2590
chr17:18271785-18274258:-	GBM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	8.0788e-04	-0.2639
chr17:18271785-18274258:-	HNSC	GSVA_HALLMARK_E2F_TARGETS	EER	5.2642e-03	-0.1324
ENSG00000177302.13,TOP3A	HNSC	GSVA_HALLMARK_E2F_TARGETS	EAG	5.3144e-03	-0.1322
ENSG00000177302.13,TOP3A	KIRC	GSVA_HALLMARK_HYPOXIA	EAG	4.0499e-02	0.1125
chr17:18271785-18274258:-	KIRC	GSVA_HALLMARK_HYPOXIA	EER	1.4952e-02	0.1337
ENSG00000177302.13,TOP3A	KIRP	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	3.3472e-02	0.1376
chr17:18271785-18274258:-	KIRP	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	2.1397e-02	0.1488
ENSG00000177302.13,TOP3A	LAML	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	7.3527e-03	-0.2679
ENSG00000177302.13,TOP3A	LGG	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	3.1492e-07	0.2233
chr17:18271785-18274258:-	LGG	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	2.8076e-07	0.2242
ENSG00000177302.13,TOP3A	LIHC	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EAG	5.9964e-04	0.2075
chr17:18271785-18274258:-	LIHC	GSVA_HALLMARK_XENOBIOTIC_METABOLISM	EER	5.9964e-04	0.2075
chr17:18271785-18274258:-	LUAD	GSVA_HALLMARK_HYPOXIA	EER	2.7429e-03	0.1498
ENSG00000177302.13,TOP3A	LUAD	GSVA_HALLMARK_HYPOXIA	EAG	2.7389e-03	0.1498
ENSG00000177302.13,TOP3A	LUSC	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	1.8399e-04	-0.1778
chr17:18271785-18274258:-	LUSC	GSVA_HALLMARK_G2M_CHECKPOINT	EER	1.5384e-04	-0.1799
ENSG00000177302.13,TOP3A	OV	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	5.2329e-05	-0.2454
chr17:18271785-18274258:-	OV	GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION	EER	9.2629e-05	0.2374
chr17:18271785-18274258:-	PCPG	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	2.5935e-02	0.1789
ENSG00000177302.13,TOP3A	PCPG	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EAG	2.5935e-02	0.1789
ENSG00000177302.13,TOP3A	PRAD	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.1152e-04	0.1822
chr17:18271785-18274258:-	PRAD	GSVA_HALLMARK_UV_RESPONSE_DN	EER	9.9489e-05	0.1834
chr17:18271785-18274258:-	SARC	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	1.2845e-04	0.2384
ENSG00000177302.13,TOP3A	SARC	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	1.5716e-04	0.2354
ENSG00000177302.13,TOP3A	SKCM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EAG	2.5402e-02	0.1046
chr17:18271785-18274258:-	SKCM	GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY	EER	2.3950e-02	0.1056
ENSG00000177302.13,TOP3A	STAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	5.3435e-05	-0.2173
chr17:18306044-18306687:-	STAD	GSVA_HALLMARK_PANCREAS_BETA_CELLS	EER	3.5492e-02	-0.4062
chr17:18287817-18288458:-	STAD	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	8.7969e-03	-0.5126
chr17:18271785-18274258:-	STAD	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	4.1163e-04	-0.1905
ENSG00000177302.13,TOP3A	TGCT	GSVA_HALLMARK_GLYCOLYSIS	EAG	5.4025e-06	-0.3562
chr17:18271785-18274258:-	TGCT	GSVA_HALLMARK_GLYCOLYSIS	EER	5.4025e-06	-0.3562
chr17:18271785-18274258:-	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EER	6.1914e-06	0.2131
ENSG00000177302.13,TOP3A	THCA	GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY	EAG	6.1914e-06	0.2131
chr17:18271785-18274258:-	THYM	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EER	4.6049e-11	0.5696
ENSG00000177302.13,TOP3A	THYM	GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB	EAG	4.6049e-11	0.5696
chr17:18271785-18274258:-	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.0561e-03	0.2505
ENSG00000177302.13,TOP3A	UCEC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.0989e-03	0.2497
ENSG00000177302.13,TOP3A	UVM	GSVA_HALLMARK_G2M_CHECKPOINT	EAG	1.8457e-02	-0.2893

Top

7. Enriched editing regions and drugs for TOP3A

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr17:18271785-18274258:-	ACC	CGP.60474	EER	1.3096e-02	0.3017
ENSG00000177302.13,TOP3A	ACC	CGP.60474	EAG	1.3096e-02	0.3017
ENSG00000177302.13,TOP3A	BLCA	AMG.706	EAG	1.3771e-03	0.1673
chr17:18271785-18274258:-	BLCA	JNK.9L	EER	1.7335e-03	-0.1639
chr17:18271785-18274258:-	BRCA	BIRB.0796	EER	4.7090e-04	0.1083
ENSG00000177302.13,TOP3A	BRCA	BIRB.0796	EAG	1.2638e-03	0.0998
chr17:18271785-18274258:-	CESC	Embelin	EER	1.3348e-02	-0.1430
ENSG00000177302.13,TOP3A	CESC	Embelin	EAG	1.3794e-02	-0.1423
ENSG00000177302.13,TOP3A	CHOL	BI.2536	EAG	2.7395e-02	0.4026
chr17:18271785-18274258:-	COAD	GW843682X	EER	5.8856e-04	0.2352
ENSG00000177302.13,TOP3A	COAD	GW843682X	EAG	9.2220e-07	0.3303
ENSG00000177302.13,TOP3A	DLBC	FTI.277	EAG	1.1984e-03	-0.4583
ENSG00000177302.13,TOP3A	ESCA	JNK.Inhibitor.VIII	EAG	1.3101e-03	-0.2519
chr17:18271785-18274258:-	ESCA	JNK.Inhibitor.VIII	EER	1.4658e-03	-0.2495
ENSG00000177302.13,TOP3A	GBM	BAY.61.3606	EAG	5.1320e-04	0.2732
chr17:18271785-18274258:-	GBM	BAY.61.3606	EER	3.5746e-04	0.2805
chr17:18271785-18274258:-	HNSC	Elesclomol	EER	8.4323e-04	0.1580
ENSG00000177302.13,TOP3A	HNSC	Elesclomol	EAG	8.5466e-04	0.1579
ENSG00000177302.13,TOP3A	KICH	Bortezomib	EAG	5.2702e-03	0.4006
ENSG00000177302.13,TOP3A	KIRC	BIBW2992	EAG	1.7390e-02	0.1307
chr17:18271785-18274258:-	KIRC	AZD6482	EER	6.9509e-03	0.1485
chr17:18271785-18274258:-	KIRP	BMS.708163	EER	1.6853e-03	-0.2021
ENSG00000177302.13,TOP3A	KIRP	AMG.706	EAG	1.9695e-03	0.1992
ENSG00000177302.13,TOP3A	LAML	LFM.A13	EAG	3.6553e-02	-0.2104
chr17:18271785-18274258:-	LAML	AICAR	EER	3.8770e-02	0.2159
chr17:18271785-18274258:-	LGG	Cytarabine	EER	3.3125e-07	0.2229
ENSG00000177302.13,TOP3A	LGG	Cytarabine	EAG	3.4443e-07	0.2226
ENSG00000177302.13,TOP3A	LIHC	Bleomycin	EAG	7.2875e-05	0.2416
chr17:18271785-18274258:-	LIHC	Bleomycin	EER	7.2875e-05	0.2416
chr17:18271785-18274258:-	LUAD	BMS.754807	EER	2.2707e-03	-0.1526
ENSG00000177302.13,TOP3A	LUAD	BMS.754807	EAG	2.1712e-03	-0.1532
ENSG00000177302.13,TOP3A	LUSC	CI.1040	EAG	2.3807e-04	-0.1747
chr17:18271785-18274258:-	LUSC	CI.1040	EER	1.5171e-04	-0.1800
ENSG00000177302.13,TOP3A	OV	Bexarotene	EAG	3.6697e-06	0.2795
chr17:18271785-18274258:-	OV	Bexarotene	EER	3.4452e-06	0.2802
ENSG00000177302.13,TOP3A	PAAD	BIBW2992	EAG	1.3536e-02	-0.2137
chr17:18271785-18274258:-	PAAD	BIBW2992	EER	1.3536e-02	-0.2137
chr17:18271785-18274258:-	PCPG	Epothilone.B	EER	1.3420e-03	0.2554
ENSG00000177302.13,TOP3A	PCPG	Epothilone.B	EAG	1.3420e-03	0.2554
chr17:18271785-18274258:-	PRAD	CCT007093	EER	1.3037e-04	-0.1804
ENSG00000177302.13,TOP3A	PRAD	CCT007093	EAG	1.1132e-04	-0.1822
ENSG00000177302.13,TOP3A	READ	Cisplatin	EAG	2.1560e-02	0.2846
chr17:18271785-18274258:-	SARC	A.443654	EER	1.7035e-07	0.3216
ENSG00000177302.13,TOP3A	SARC	A.443654	EAG	1.8305e-07	0.3208
ENSG00000177302.13,TOP3A	SKCM	BAY.61.3606	EAG	5.0960e-04	0.1620
chr17:18271785-18274258:-	SKCM	BAY.61.3606	EER	5.6269e-04	0.1607
ENSG00000177302.13,TOP3A	STAD	BAY.61.3606	EAG	1.6193e-02	0.1303
chr17:18287817-18288458:-	STAD	AMG.706	EER	2.1292e-06	-0.7943
chr17:18271785-18274258:-	STAD	BAY.61.3606	EER	2.0398e-02	0.1257
ENSG00000177302.13,TOP3A	TGCT	Docetaxel	EAG	1.3534e-06	0.3767
chr17:18271785-18274258:-	TGCT	Docetaxel	EER	1.3534e-06	0.3767
chr17:18271785-18274258:-	THCA	Cytarabine	EER	1.4226e-04	0.1800
ENSG00000177302.13,TOP3A	THCA	Cytarabine	EAG	1.4226e-04	0.1800
chr17:18271785-18274258:-	THYM	AZD8055	EER	1.0486e-14	0.6464
ENSG00000177302.13,TOP3A	THYM	AZD8055	EAG	1.0486e-14	0.6464
chr17:18271785-18274258:-	UCEC	Metformin	EER	1.5016e-03	0.2430
ENSG00000177302.13,TOP3A	UCEC	Metformin	EAG	1.5729e-03	0.2420
chr17:18271785-18274258:-	UCS	EHT.1864	EER	1.4913e-02	0.3267
ENSG00000177302.13,TOP3A	UCS	EHT.1864	EAG	1.4913e-02	0.3267
ENSG00000177302.13,TOP3A	UVM	ATRA	EAG	8.6937e-04	0.4002

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType